上皮瘤治疗市场 - 全球产业规模、份额、趋势、机会及预测（按类型、药物类别、分销管道、地区和竞争格局划分，2021-2031年）

全球上皮瘤治疗市场预计将从 2025 年的 52.2 亿美元成长到 2031 年的 87.5 亿美元，复合年增长率为 8.99%。

该市场专注于治疗性介入上皮来源肿瘤，特别是基底细胞癌和鳞状细胞癌。其主要成长驱动因素包括：由于紫外线累积照射导致全球皮肤恶性肿瘤发生率上升，以及人口老化加剧了人们对肿瘤疾病的易感性。此外，意识提升以及非侵入性治疗方法的进步也显着推动了对有效治疗方案的需求。

儘管存在这些积极趋势，但市场仍面临许多障碍。根据美国癌症协会的数据，预计到2024年，美国将新增约100,640例黑色素瘤病例，凸显了普及医疗保健的迫切需求。然而，先进免疫疗法和标靶药物的高成本构成了一项重大挑战。这种经济负担往往限制了患者获得新疗法的机会，使医保报销机制复杂化，并可能阻碍市场进一步扩张。

市场驱动因素

全球基底细胞癌和鳞状细胞癌发生率的不断上升是推动全球上皮瘤治疗市场发展的主要因素。这一增长主要归因于紫外线照射的累积以及人口老化加剧，老年人患皮肤恶性肿瘤的风险更高。随着患者数量的增加，医疗保健系统也面临手术切除和局部治疗需求的相应增长，以应对日益沉重的负担。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》报告，光是在美国，每年就有约540万例基底细胞癌和鳞状细胞癌确诊病例。此外，澳洲辐射防护与核能在2024年预测，到2050年，基底细胞癌的发生率将增加148%，这将确保对治疗性介入的长期持续需求。

标靶治疗和免疫调节剂的技术突破正在同时革新进行性和转移性上皮肿瘤的治疗模式。程序性死亡蛋白-1 (PD-1) 抑制剂的商业化为不适合传统手术或放射治疗的患者提供了有效的替代方案。这些创新正在迅速普及，大型製药公司的收入显着增长便印证了这一点。例如，2024年2月，再生元製药公司报告称，其用于治疗皮肤鳞状细胞癌的主要免疫疗法Libtayo的全球净销售额在2023年飙升50%，达到8.69亿美元。这一强劲的财务表现凸显了先进治疗方法的积极应用，从而推动了对肿瘤学研究的进一步投资，并扩大了患者获得拯救生命的生物疗法的机会。

市场挑战

先进免疫疗法和标靶治疗的高昂成本严重阻碍了上皮肿瘤治疗领域的发展。这些高成本造成了复杂的健保报销环境，保险公司经常限制对新型高价值药物的承保。因此，患者往往需要承担高额的自付费用，限制了这些治疗方法的普及，迫使医疗服务提供者依赖价格更低廉的传统治疗方法。这种价格敏感度直接降低了製药公司的收入潜力，并延缓了创新治疗方法的商业化。

考虑到非黑色素瘤皮肤癌的临床疗效，这些经济障碍的影响更为显着。根据美国癌症协会预测，到2024年，基底细胞癌和鳞状细胞癌预计将在美国造成约2,000人死亡。虽然这一死亡人数凸显了有效治疗性介入的紧迫性，但临床需求与治疗费用之间的脱节阻碍了市场扩张的潜力。新兴治疗方法的定价模式往往超过医疗保险机构的报销门槛，导致市场难以将不断增长的疾病盛行率转化为持续的商业性成长。

市场趋势

全球上皮瘤治疗市场目前正经历着向非侵入性和微创治疗方法的重大转变，这主要受患者对无疤痕治疗方法切除方案的需求所驱动。这一趋势的特征是影像导引浅层放射治疗（IG-SRT）的日益普及。 IG-SRT是一种能够精准地将治疗剂量传送到基底细胞癌部位，且不会影响患者日常生活的技术。这种治疗方法越来越受欢迎，尤其是在追求更佳美容效果的患者中，促使皮肤科诊所拓展其非手术治疗计画。根据Sensus Healthcare公司（2025年11月）发布的2025年第三季财务报告，该公司「公平交易」合约模式下的治疗数量在第三季度较第二季度增长了20%，证实了这种非侵入性治疗方法在临床上的快速应用。

同时，个人化医疗和基因组分析的应用正在从根本上改变高风险皮肤恶性肿瘤的临床决策。临床医师正积极利用超越传统分期系统的先进基因表现分析，以准确预测鳞状细胞癌的转移风险，并制定个人化的治疗方案。这种精准的风险分层使医疗服务提供者能够识别真正受益于辅助性治疗的患者，同时避免低风险患者接受不必要的手术。这种向生物学指导治疗的转变得益于诊断利用率的显着提高。根据Castle Biosciences公司于2025年11月发布的“2025年第三季财务业绩”，该公司在截至2025年9月30日的九个月内发布了13,323份DecisionDx-SCC检测报告，这表明该公司越来越依赖基因组数据来优化患者照护路径。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球上皮瘤治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（基底细胞上皮瘤、鳞状细胞癌、其他上皮肿瘤）
  • 依药物类别（刺猬讯号路径抑制剂、免疫查核点抑制剂、化疗药物、其他）
  • 通路（医院药房、零售药房、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美上皮肿瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲上皮肿瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区上皮肿瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲上皮肿瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲上皮肿瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球上皮瘤治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Roche
• Merck
• Novartis
• Pfizer
• Bristol-Myers Squibb
• Sanofi
• Eli Lilly
• AstraZeneca
• Takeda
• Regeneron

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Epithelioma Treatment Market is projected to expand from a valuation of USD 5.22 Billion in 2025 to USD 8.75 Billion by 2031, progressing at a CAGR of 8.99%. This market centers on therapeutic interventions for tumors originating from the epithelium, specifically targeting Basal Cell Carcinoma and Squamous Cell Carcinoma. Key catalysts for growth include the rising global incidence of skin malignancies due to cumulative ultraviolet radiation exposure and an aging population increasingly susceptible to oncological conditions. Additionally, heightened public awareness regarding early skin examinations and advancements in non-invasive therapeutic modalities are significantly boosting the demand for effective treatment solutions.

Despite this positive trajectory, the market faces considerable impediments. Data from the American Cancer Society indicates that in 2024, approximately 100,640 new cases of melanoma were projected to be diagnosed in the United States, highlighting the urgent need for accessible care; however, the elevated costs associated with advanced immunotherapies and targeted pharmaceutical agents present a formidable challenge. This financial burden often restricts patient access to novel treatments and adds complexity to reimbursement landscapes, potentially hindering broader market expansion.

Market Driver

The escalating global prevalence of Basal Cell Carcinoma and Squamous Cell Carcinoma serves as the primary force driving the Global Epithelioma Treatment Market. This surge is largely attributed to cumulative ultraviolet radiation exposure and demographic shifts toward an older population susceptible to cutaneous malignancies. As patient numbers rise, healthcare systems are witnessing a parallel increase in the demand for surgical excisions and topical treatments to manage this growing burden. According to the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024, an estimated 5.4 million basal and squamous cell skin cancers are diagnosed annually in the United States alone. Furthermore, the Australian Radiation Protection and Nuclear Safety Agency projected in 2024 that the incidence of basal cell carcinoma would increase by 148% by 2050, ensuring sustained long-term demand for therapeutic interventions.

Technological breakthroughs in targeted therapies and immunomodulators are simultaneously revolutionizing the treatment landscape for advanced and metastatic epitheliomas. The commercialization of programmed cell death protein-1 (PD-1) inhibitors has provided effective alternatives for patients ineligible for conventional surgery or radiation. These innovations are rapidly gaining traction, evidenced by substantial revenue growth for key pharmaceutical players; for instance, Regeneron Pharmaceuticals, Inc. reported in February 2024 that global net sales for Libtayo, a primary immunotherapy for cutaneous squamous cell carcinoma, surged by 50% to reach $869 million in 2023. This robust financial performance highlights the aggressive adoption of sophisticated therapeutics, encouraging further investment in oncology research and widening access to life-saving biologic treatments.

Market Challenge

The substantial expense associated with advanced immunotherapies and targeted pharmaceutical agents acts as a significant barrier to the growth of the epithelioma treatment sector. These elevated costs create a difficult reimbursement environment where insurance providers frequently restrict coverage for newer, high-value drugs. Consequently, patients often face prohibitive out-of-pocket expenditures, which limits the adoption rate of these therapies and forces healthcare providers to rely on older, less expensive alternatives. This price sensitivity directly reduces the potential revenue volume for pharmaceutical developers and slows the commercialization of innovative solutions.

The impact of these financial barriers is magnified when considering the clinical outcomes associated with non-melanoma skin cancers. According to the American Cancer Society, in 2024, approximately 2,000 people were projected to die from basal and squamous cell skin cancers in the United States. While this mortality figure highlights the critical need for effective therapeutic intervention, the disparity between the clinical demand and the affordability of care hampers market scalability. As the pricing models for emerging therapies often exceed the reimbursement thresholds set by healthcare payers, the market struggles to convert the rising disease prevalence into sustained commercial expansion.

Market Trends

The Global Epithelioma Treatment Market is currently experiencing a decisive shift toward non-invasive and minimally invasive modalities, driven by patient demand for scar-free alternatives to traditional surgical excisions. This trend is characterized by the increasing adoption of Image-Guided Superficial Radiation Therapy (IG-SRT), a technology that delivers precise therapeutic doses to Basal Cell and Squamous Cell Carcinomas without disrupting daily activities. This modality is particularly gaining traction among patients seeking superior cosmetic outcomes, prompting dermatology practices to expand their non-surgical service offerings. According to Sensus Healthcare, Inc., November 2025, in the 'Third Quarter 2025 Financial Results', the treatment volume under the company's Fair Deal Agreement model increased by 20% in the third quarter compared to the second quarter of 2025, underscoring the rapid clinical uptake of this non-invasive intervention.

Simultaneously, the implementation of personalized medicine and genomic profiling is fundamentally reshaping clinical decision-making for high-risk cutaneous malignancies. Clinicians are increasingly utilizing advanced gene expression profile tests to accurately predict the risk of metastasis in Squamous Cell Carcinoma, moving beyond traditional staging systems to tailor treatment intensity. This precise risk stratification enables healthcare providers to identify patients who truly benefit from adjuvant therapies while sparing low-risk individuals from unnecessary procedures. This shift towards biologically guided management is evidenced by significant diagnostic utilization; according to Castle Biosciences, Inc., November 2025, in the 'Third Quarter 2025 Results', the company delivered 13,323 DecisionDx-SCC test reports during the nine months ended September 30, 2025, highlighting the growing reliance on genomic data to optimize patient care pathways.

Key Market Players

• Roche
• Merck
• Novartis
• Pfizer
• Bristol-Myers Squibb
• Sanofi
• Eli Lilly
• AstraZeneca
• Takeda
• Regeneron

Report Scope

In this report, the Global Epithelioma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epithelioma Treatment Market, By Type

• Basal Cell Epithelioma
• Squamous Cell Epithelioma
• Other Epitheliomas

Epithelioma Treatment Market, By Drug Class

• Hedgehog Pathway Inhibitors
• Immune Checkpoint Inhibitors
• Chemotherapeutic Agents
• Others

Epithelioma Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other

Epithelioma Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Epithelioma Treatment Market.

Available Customizations:

Global Epithelioma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epithelioma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Basal Cell Epithelioma, Squamous Cell Epithelioma, Other Epitheliomas)
  • 5.2.2. By Drug Class (Hedgehog Pathway Inhibitors, Immune Checkpoint Inhibitors, Chemotherapeutic Agents, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Epithelioma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Epithelioma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Epithelioma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Epithelioma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel

7. Europe Epithelioma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Epithelioma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Epithelioma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Epithelioma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Epithelioma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Epithelioma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Epithelioma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Epithelioma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Epithelioma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Epithelioma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Epithelioma Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Epithelioma Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Epithelioma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Epithelioma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Epithelioma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Epithelioma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. South America Epithelioma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Epithelioma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Epithelioma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Epithelioma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Epithelioma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Roche
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck
• 15.3. Novartis
• 15.4. Pfizer
• 15.5. Bristol-Myers Squibb
• 15.6. Sanofi
• 15.7. Eli Lilly
• 15.8. AstraZeneca
• 15.9. Takeda
• 15.10. Regeneron

16. Strategic Recommendations

17. About Us & Disclaimer